| HSIC |
Report |
Q2 2026 non-GAAP diluted EPS |
IN-LINE |
pred ~$1.28 vs. cons $1.27 |
MEDIUM |
| HSIC |
Report |
Q2 2026 total net sales |
IN-LINE |
pred ~$3.39B vs. cons $3.37B |
MEDIUM |
| HSIC |
Report |
Q2 2026 Adjusted EBITDA |
BEAT |
pred ~$279M vs. cons $276M |
MEDIUM |
| HSIC |
Guide |
FY 2026 non-GAAP diluted EPS guidance |
UNCHANGED |
guide ~$5.30 midpoint vs. cons $5.31 (FY 2026) |
HIGH |
| HSIC |
Guide |
FY 2026 total sales-growth guidance |
UNCHANGED |
guide ~4.0% midpoint vs. cons 4.1% (FY 2026) |
HIGH |
| HSIC |
Guide |
FY 2026 Adjusted EBITDA-growth guidance |
UNCHANGED |
guide ~5.0% vs. cons 5.1% (FY 2026) |
MEDIUM |
| HSIC |
Guide |
Year-end value-creation savings run-rate commentary |
UNCHANGED |
guide ~$125M vs. cons ~$125M (exit-rate at FY 2026 year-end) |
MEDIUM |
| HSIC |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| HSIC |
Return |
5-day cumulative residual |
+0.5% (FADE) |
A modest Q2 EBITDA beat (~$279M vs. ~$276M) and reaffirmed FY EPS midpoint (~$5.30 vs. ~$5.31 consensus) should support an initial ~+1.5% residual move, but unchanged out-period math leaves limited basis for upward FY 2026/FY 2027 revisions; the residual gain is expected to fade to ~+0.5% by day 5. |
MEDIUM |